Trial Profile

A Phase I Trial of Radioimmunotherapy (Y-90-Mx-DTPA-cT84.66) After Completion of Radiation Therapy Alone, or Radiation Therapy Plus Systemic Therapy in Unresectable or Medically Inoperable, Non-metastatic CEA-Producing Stage I-IIIB Non-Small Cell Lung Cancer.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-CEA monoclonal antibody 111In-mT84-66 (Primary) ; Anti-CEA monoclonal antibody cT84-66-Y-90 (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel
Indications Non-small cell lung cancer
Focus Adverse reactions

13 Feb 2018 Biomarkers information updated
08 Aug 2013 Planned end date changed from 1 Aug 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.
08 Aug 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com